EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis

Yousef R Badran, Fangwen Zou, Sienna M Durbin, Barbara E Dutra, Hamzah Abu-Sbeih, Anusha S Thomas, Mehmet Altan iD, John A Thompson, Wei Qiao, Donna E Leet, Po-Ying Lai, Nora K Horick und 4 weitere

Journal for ImmunoTherapy of Cancer · 2023-06 · 11 (6) · e007195

DOI: 10.1136/jitc-2023-007195 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.06.2023. Verfasst von Yousef R Badran und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Enterocolitis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Fariborz Maseeh Award for Innovative Medical Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immune checkpoint inhibitor (ICI) therapy is often suspended because of immune-related enterocolitis (irEC). We examined the effect of resumption of ICIs with or without concurrent selective immunosuppressive therapy (SIT) on rates of symptom recurrence and survival outcomes.

Methods

This retrospective, multicenter study examined patients who were treated with ICI and developed irEC requiring SIT (infliximab or vedolizumab) for initial symptom control or to facilitate steroid tapering between May 2015 and June 2020. After symptom resolution, patients were restarted either on ICI alone or on concurrent ICI and SIT at the discretion of the treating physicians. The associations between irEC recurrence and treatment group were assessed via univariate analyses and multivariate logistic regression. Cox proportional hazards model was used for survival analysis.

Results

Of the 138 included patients who required SIT for initial irEC symptom control, 61 (44.2%) patients resumed ICI without concurrent SIT (control group) and 77 (55.8%) patients resumed ICI therapy with concurrent SIT: 33 with infliximab and 44 with vedolizumab. After symptom resolution, patients in the control group were more commonly restarted on a different ICI regimen (65.6%) compared with those receiving SIT (31.2%) (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalEnterocolitisHumansImmune Checkpoint InhibitorsInfliximabRetrospective StudiesImmunosuppression Therapy

Stichwörter der Autor:innen

AutoimmunityImmune Checkpoint InhibitorsImmunotherapyInflammation

Substanzen

Immune Checkpoint InhibitorsInfliximabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
  • Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

ORCID-Profile: Mehmet Altan, Michael A Postow, David M Faleck, Yinghong Wang, Michael Dougan

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • Fariborz Maseeh Award for Innovative Medical Education
  • National Cancer Institute
  • The Peter and Ann Lambertus Family Foundation
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Badran, Y. R., Zou, F., Durbin, S. M., Dutra, B. E., Abu-Sbeih, H., Thomas, A. S., Altan, M., Thompson, J. A., Qiao, W., Leet, D. E., Lai, P. Y., Horick, N. K., Postow, M. A., Faleck, D. M., Wang, Y., & Dougan, M. (2023). Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer, 11(6), e007195. https://doi.org/10.1136/jitc-2023-007195

Vancouver

Badran YR, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, et al. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer. 2023;11(6):e007195. doi:10.1136/jitc-2023-007195

BibTeX
@article{Badran2023,
  author = {Badran, Yousef R and Zou, Fangwen and Durbin, Sienna M and Dutra, Barbara E and Abu-Sbeih, Hamzah and Thomas, Anusha S and Altan, Mehmet and Thompson, John A and Qiao, Wei and Leet, Donna E and Lai, Po-Ying and Horick, Nora K and Postow, Michael A and Faleck, David M and Wang, Yinghong and Dougan, Michael},
  title = {Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {6},
  pages = {e007195},
  doi = {10.1136/jitc-2023-007195}
}
Kostenlos starten →